Loading viewer...
investor_presentation
Format: PDF investor_presentation
Regeneron Pharmaceuticals investor presentation dated June 2020.
This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual
events orresults may differ materially from these forward -looking statements .Words such as“anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations ofsuch words, andsimilar expressions areintended
toidentify such forward -looking statements, although notallforward -looking statements contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact of
SARS -CoV-2(thevirus thathascaused theCOVID -19pandemic) onRegeneron's business anditsemployees, collaborators, suppliers, andother third parties onwhich Regeneron relies, Regeneron's anditscollaborators’
ability tocontinue toconduct research and clinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed byRegeneron and/or itscollaborators (collectively, "Regeneron’s
Products"), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products andRegeneron’s product candidates andresearch andclinical programs now underway or
planned, including without limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab), Libtayo®(cemiplimab), Praluent®(alirocumab), Kevzara®(sarilumab), fasinumab, evinacumab, garetosmab ,pozelimab ,Regeneron’s
oncology programs (including itscostimulatory bispecific portfolio andother therapeutic approaches discussed inthispresentation), Regeneron’s COVID -19antibody program andother earlier -stage product candidates, and
theuseofhuman genetics inRegeneron’s research programs ;theextent towhich theresults from theresearch anddevelopment programs orpreclinical testing conducted byRegeneron oritscollaborators (including the
research anddevelopment programs andpreclinical testing discussed inthispresentation) may bereplicated inother studies andmay lead toadvancement ofproduct candidates toclinical trials ortherapeutic applications ;
unforeseen safety issues resulting from theadministration ofRegeneron’s Products andproduct candidates inpatients, including serious complications orside effects inconnection with theuseofRegeneron’s product
candidates inclinical trials ;thelikelihood andtiming ofpossible regulatory approval andcommercial launch ofRegeneron’s late-stage product candidates andnew indications forRegeneron’s Products, including without
limitation EYLEA, Dupixent, Libtayo, Praluent, Kevzara, fasinumab, evinacumab, REGN -EB3,garetosmab ,pozelimab ,andREGN 1979 ;thelikelihood andtiming ofachieving anyoftheanticipated milestones described inthis
presentation ;ongoing regulatory obligations andoversight impacting Regeneron’s Products (such asEYLEA, Dupixent, Libtayo, Praluent, andKevzara), research andclinical programs, andbusiness, including those relating
Preview truncated — download the full document for the complete content.
investor_presentation
23 Pages
Vale
Albaraka Türk Q4 2023 Investor Presentation
investor_presentationinvestor_presentation
20 Pages
Albaraka Türk Participation Bank